• Merck (NYSE:MRK) plans to present new cardiopulmonary data at ACC.26, including the first Phase 3 results for its oral PCSK9 inhibitor enlicitide.
• The company will also share fresh findings for WINREVAIR in pulmonary hypertension and challenging heart failure settings.
• The data presentations are part of Merck's push to build a late stage pipeline outside oncology as investor attention grows on post Keytruda growth drivers.

For investors tracking NYSE:MRK, this update is important because it shifts focus from the oncology franchise to the broader cardiopulmonary pipeline. Cardiovascular disease and heart failure represent large treatment areas, and oral PCSK9 therapy could be relevant for patients and payers if trial results ultimately support real world use.

The ACC.26 data will give investors more information on how enlicitide and WINREVAIR might fit into Merck's longer term product mix. While outcomes are still subject to ongoing clinical and regulatory steps, this event adds another piece to the picture as the company prepares for a future where Keytruda patents expire.

Stay updated on the most important news stories for Merck by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merck.

For investors, the ACC.26 readouts give a clearer view of how Merck is trying to build a cardiopulmonary pillar that sits alongside oncology. Positive Phase 3 data for enlicitide supports the idea that oral PCSK9 therapy could become part of real world cholesterol management, which matters in a field where injectable PCSK9 drugs from Amgen, Sanofi and Regeneron already exist. The Phase 2 WINREVAIR data in complex pulmonary hypertension and heart failure also feeds into the broader thesis that Merck is pushing deeper into cardiovascular and pulmonary disease, areas flagged by analysts as important future growth drivers.

How This Fits Into The Merck Narrative

• The cardiopulmonary data aligns with the narrative that Merck is building more than 20 potential growth drivers, with WINREVAIR specifically cited as one of the products contributing to that pipeline.
• Success for enlicitide and WINREVAIR raises the execution bar, which could challenge parts of the narrative that focus on policy and pricing pressures if real world uptake does not match expectations.
• The specific competitive dynamics around an oral PCSK9 drug are not fully captured in the narrative, which focuses more on overall pipeline breadth than individual cardiometabolic franchises.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Merck to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged a high level of debt, so funding multiple late stage programs while preparing for Keytruda patent expiry adds financial and execution risk.
• ⚠️ If the new cardiopulmonary drugs do not gain reimbursement support or face strong competition from existing treatments at companies like Amgen, Pfizer and AstraZeneca, they may not offset future revenue pressures.
• 🎁 Merck is described as trading at good value compared with peers and industry and about 44.5% below one fair value estimate, which some investors may see as supportive while the pipeline matures.
• 🎁 Earnings have grown 18.1% per year over the past 5 years and are forecast to grow 8.32% per year, alongside a reliable 2.95% dividend yield, giving investors both pipeline exposure and an income stream.

What To Watch Going Forward

From here, focus on detailed efficacy and safety data for enlicitide and WINREVAIR, any guidance on regulatory filings and how payers respond to an oral PCSK9 option versus established injectables. It is also worth tracking how analysts update earnings models as cardiopulmonary contributions become clearer and how that interacts with views on debt, Gardasil trends and the Keytruda expiry. The way these pieces fit together will shape how durable Merck’s post Keytruda story looks.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Merck, head to the community page for Merck to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.